All 18 COVID-19 patients hospitalized with moderate or severe symptoms who received the drug Amor-18 developed by Israeli biotech company Amorphical recovered and were discharged in a few days, the company announced on Wednesday. Of the 19 individuals who were given a placebo, six had to be transferred to intensive care, and two died.
As part of compassionate care, two other patients in a very serious condition were given the drug. Both recovered and were discharged.
“Since the patients treated with the drug recovered within a few days and were released to their home, this was 100% successful,” said Dr. Nashat Abu Saleh, co-director of the coronavirus department at Ziv Medical Center in Safed, where the phase II clinical trial was conducted.
Amor-18, which uses Amorphous Calcium Carbonate (ACC) as the main ingredient, was administered orally or by inhalation. As explained by the company, ACC has the ability to modulate acidic pH changes around each cell. These changes affect the capability of COVID-19 to penetrate the cells and replicate. This allows the drug to prevent the virus from spreading and thus the patients from deteriorating.
If all the above is true this is going to be some serious competition to the big pharma drugs.